Free Trial

Biodexa Pharmaceuticals (BDRX) SEC Filings & 10K Form

Biodexa Pharmaceuticals logo
$7.13 +0.33 (+4.85%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$7.10 -0.03 (-0.42%)
As of 08/8/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Biodexa Pharmaceuticals SEC Filings

DateFilerForm TypeView
07/31/2025
8:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/18/2025
4:23 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
07/18/2025
4:23 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
07/18/2025
4:23 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
06/27/2025
4:15 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
06/27/2025
4:16 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
06/27/2025
4:16 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
06/13/2025
3:19 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/02/2025
4:23 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
06/02/2025
4:24 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
05/30/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2025
4:59 PM
Biodexa Pharmaceuticals (Subject)
C/M CAPITAL PARTNERS, LP (Filed by)
Form SCHEDULE 13G
05/22/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2025
4:16 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
05/15/2025
4:16 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
05/12/2025
7:31 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2025
11:15 PM
Biodexa Pharmaceuticals (Filer)
Form EFFECT
05/11/2025
11:15 PM
Biodexa Pharmaceuticals (Filer)
Form EFFECT
05/11/2025
11:15 PM
Biodexa Pharmaceuticals (Filer)
Form EFFECT
05/12/2025
5:02 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
05/12/2025
5:02 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
05/12/2025
5:02 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
04/29/2025
3:15 PM
Biodexa Pharmaceuticals (Filer)
Form POS AM
04/17/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2025
7:41 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2025
7:43 AM
Biodexa Pharmaceuticals (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/10/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/10/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/24/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
3:30 PM
Biodexa Pharmaceuticals (Subject)
C/M CAPITAL PARTNERS, LP (Filed by)
Form SCHEDULE 13G
02/13/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/10/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/27/2025
11:15 PM
Biodexa Pharmaceuticals (Filer)
Form EFFECT
01/28/2025
5:00 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/22/2025
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/21/2025
5:27 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/21/2025
5:30 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/21/2025
5:18 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/21/2025
5:21 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
HIDDEN IN THE BOOK OF GENESIS… (Ad)

“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.

Watch Jim Rickards reveal the Old Testament Wealth Code
01/21/2025
5:24 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/21/2025
5:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/21/2025
5:15 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/17/2025
3:49 PM
Biodexa Pharmaceuticals (Filer)
Form F-1
Registration statement for securities of certain foreign private issuers  
01/17/2025
3:21 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/08/2025
5:00 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:03 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:06 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:09 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:15 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
01/08/2025
5:18 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
12/27/2024
4:15 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2024
10:56 AM
Biodexa Pharmaceuticals (Subject)
Brio Capital Master Fund Ltd. (Filed by)
Form SC 13G/A
11/05/2024
5:09 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:15 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:06 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:06 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:00 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/05/2024
5:03 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
11/01/2024
4:18 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/16/2024
8:12 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
10/15/2024
4:14 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/04/2024
7:30 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/27/2024
3:41 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/26/2024
7:42 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/20/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/19/2024
3:30 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/16/2024
7:40 AM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
Altucher: Trump’s Great Gain is starting (Ad)

New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.

See Altucher’s Trump crypto prediction here
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
09/06/2024
6:54 PM
Biodexa Pharmaceuticals (Filer)
Form 424B3
08/30/2024
3:38 PM
Biodexa Pharmaceuticals (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2024
11:15 PM
Biodexa Pharmaceuticals (Filer)
Form EFFECT
08/20/2024
5:00 AM
Biodexa Pharmaceuticals (Filer)
Form 424B3
08/12/2024
3:36 PM
Biodexa Pharmaceuticals (Filer)
Form F-1
Registration statement for securities of certain foreign private issuers  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:BDRX) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners